We are live on ! Find out more
GCIA

Gabelli & Co Investment Advisers Portfolio holdings

AUM $674M
1-Year Est. Return 64.46%
This Fund
S&P 500
This Quarter Est. Return
+14.52%
1 Year Est. Return
+64.46%
3 Year Est. Return
+233.2%
5 Year Est. Return
+564.06%
10 Year Est. Return
+5,311.56%
AUM
$651M
AUM Growth
-$10.4M
Cap. Flow
-$40.4M
Cap. Flow %
-6.21%
Top 10 Hldgs %
33.34%
Holding
313
New
62
Increased
51
Reduced
31
Closed
48

Sector Composition

Rank Sector Weight
1 Healthcare 17.22%
2 Communication Services 15.3%
3 Technology 11.49%
4 Industrials 8.49%
5 Consumer Discretionary 8.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ITCI
301
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-202,300
Closed -$26.7M
TBNK
302
DELISTED
Territorial Bancorp Inc.
TBNK
-51,741
Closed -$434K
DM
303
DELISTED
Desktop Metal, Inc.
DM
-301,515
Closed -$1.48M
VOXX
304
DELISTED
VOXX International Corporation Class A
VOXX
-347,050
Closed -$2.6M
PTVE
305
DELISTED
Pactiv Evergreen Inc. Common stock
PTVE
-302,250
Closed -$5.44M
VBFC
306
DELISTED
Village Bank and Trust Financial Corp.
VBFC
-4,050
Closed -$325K
FBMS
307
DELISTED
The First Bancshares, Inc.
FBMS
-27,983
Closed -$946K
IVAC
308
DELISTED
Intevac Inc
IVAC
-204,690
Closed -$818K
ML
309
DELISTED
MoneyLion Inc.
ML
-31,300
Closed -$2.71M
SWI
310
DELISTED
SolarWinds Corporation Common Stock
SWI
-106,600
Closed -$1.96M
PGACU
311
Pantages Capital Acquisition Corp Unit
PGACU
-203,200
Closed -$2.08M

Similar funds

Gabelli & Co Investment Advisers's Q2 2025 Portfolio in Review

As of Q2 2025, Gabelli & Co Investment Advisers held 313 positions worth $651M, down 1.6% from $662M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Gabelli & Co Investment Advisers withdrew a net $40.4M in Q2 2025, closing 48 positions and reducing 31 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $26.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Gabelli & Co Investment Advisers opened a new position in Blueprint Medicines worth $23.5M.

  • Gabelli & Co Investment Advisers's largest Q2 2025 buy was Blueprint Medicines: 183,374 shares worth $23.5M.
  • Gabelli & Co Investment Advisers added most to SpringWorks Therapeutics in Q2 2025, an estimated $12.6M increase.
  • Gabelli & Co Investment Advisers's biggest Q2 2025 reduction was Albertsons Companies, cutting an estimated $4.03M.
  • Gabelli & Co Investment Advisers fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $26.7M.
  • Gabelli & Co Investment Advisers's ten largest holdings make up 33% of its $651M portfolio in Q2 2025.
  • Gabelli & Co Investment Advisers opened 62 new positions and closed 48 in Q2 2025.
  • Gabelli & Co Investment Advisers's portfolio value fell 1.6% quarter-over-quarter to $651M.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.